脑部单次与多次立体定向放疗的剂量体积耐受性
该研究汇总1995—2018年PubMed收录的51篇报告,分析单次或分次立体定向放疗后脑放射性坏死的剂量体积预测因子。脑转移单次SRS时V12为5 cm³、10 cm³或>15 cm³对应症状性放射性坏死风险约10%、15%、20%;分次SRS可降低大体积治疗时的坏死风险。
要点
- 脑转移单次SRS的V12 5 cm³、10 cm³、>15 cm³对应症状性放射性坏死风险约10%、15%、20%。
- 分次SRS较单次SRS可降低大体积治疗时的放射性坏死风险。
- 脑转移分3次V20或分5次V24<20 cm³时,任何坏死或水肿风险<10%,需手术的坏死风险<4%。
核心结论
- SRS和fSRS后放射性坏死风险可建模为剂量与治疗体积的函数,fSRS相对SRS可降低大体积治疗的放射性坏死风险。
研究设计与样本
- 美国医学物理学家协会立体定向体部放疗工作组汇总1995—2018年PubMed收录的51篇报告,分析脑SRS/fSRS后放射性坏死、水肿或症状的NTCP及剂量体积指标。
- 排除仅含胶质瘤、脑膜瘤、前庭神经鞘瘤或脑干靶区的患者,数据总结与分析聚焦于动静脉畸形(AVM)和脑转移。
主要发现
- 报告间放射性坏死发生率差异很大,脑转移的SRS/fSRS数据比AVM数据更适合NTCP建模。
- 脑转移SRS/fSRS相关放射性坏死与肿瘤进展难以区分。
- 脑转移单次SRS时,包括靶区在内的组织V12为5 cm³、10 cm³或>15 cm³分别与症状性放射性坏死风险约10%、15%、20%相关。
- AVM的SRS在同等V12下症状性放射性坏死率略低于脑转移。
- 脑转移分3次V20或分5次V24<20 cm³与任何坏死或水肿风险<10%、需切除的放射性坏死风险<4%相关。
关键数值与推荐
- 脑转移单次SRS:V12=5 cm³对应症状性放射性坏死风险约10%。
- 脑转移单次SRS:V12=10 cm³对应症状性放射性坏死风险约15%。
- 脑转移单次SRS:V12>15 cm³对应症状性放射性坏死风险约20%。
- 脑转移分3次:V20<20 cm³对应任何坏死或水肿风险<10%、需切除的放射性坏死风险<4%。
- 脑转移分5次:V24<20 cm³对应任何坏死或水肿风险<10%、需切除的放射性坏死风险<4%。
临床怎么用
- 脑转移单次SRS规划时可参考V12 5、10、>15 cm³对应的约10%、15%、20%症状性放射性坏死风险。
- 脑转移分3次或5次SRS时,可将V20或V24控制在<20 cm³以降低坏死或水肿风险。
- 大体积治疗时优先考虑分次SRS以降低放射性坏死风险。
- 脑转移SRS/fSRS后放射性坏死需与肿瘤进展鉴别。
局限性
- 报告间放射性坏死发生率差异很大,数据异质性明显。
- 脑转移数据比AVM数据更适合NTCP建模,AVM建模受限。
- 需更标准化的剂量体积与毒性报告以支持未来汇总分析并细化预测模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). METHODS AND MATERIALS: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases. RESULTS: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection. CONCLUSIONS: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
引用
- Milano MT, Grimm J, Niemierko A, et al. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. Int J Radiat Oncol Biol Phys. 2020. PMID: 32921513. doi:10.1016/j.ijrobp.2020.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。